CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the American Epilepsy Society (AES) 70th Annual Meeting, taking place December 2-6, 2016 in Houston, TX. Members of the company’s medical affairs team will be accessible at booth number 918.
Below is the schedule for the presentations and a Sage-sponsored scientific exhibit:
Date: Saturday, December 3, 2016Poster Presentation Time: 12:00 p.m. – 6:00 p.m. CTLocation: Hall A3/Level 3, George R. Brown Convention CenterPoster Number: 1.261Title: SAGE-217, a next generation neuroactive steroid positive allosteric modulator of synaptic and extra-synaptic GABAA receptors, is active against audiogenic seizures in Fmr1 knockout mice
Date: Sunday, December 4, 2016Poster Presentation Time: 10:00 a.m. – 4:00 p.m. CTLocation: Hall A3/Level 3, George R. Brown Convention CenterPoster Number: 2.187Title: SGE-516, a next generation neuroactive steroid, reduces status epilepticus (SE) after a 20 or 40-minute treatment delay in a rat model of soman intoxication
Date: Sunday, December 4, 2016Poster Presentation Time: 10:00 a.m. – 4:00 p.m. CTLocation: Hall A3/Level 3, George R. Brown Convention CenterPoster Number: 2.185Title: SAGE-689, a potent and selective next generation neuroactive steroid, reduces electrographic seizure activity in a rat model of pharmacoresistant status epilepticus while phenytoin does not
Date: Sunday, December 4, 2016Sage Sponsored Scientific Exhibit Time: 2 p.m. – 5 p.m. CTLocation: Room 360 ADTitle: Neuroactive Steroids in the Treatment of GABAA-Related Disorders.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161201006314/en/
 .bwalignc {text-align: center !important;} ;}